视频：对话 Catalent 细胞治疗全球现场应用科学家与战略联盟负责人 John Tomtishen
Video: Sitting Down With… John Tomtishen
Catalent 细胞治疗全球现场应用科学家与战略联盟负责人 John Tomtishen 在 IBTV 合作制作的视频访谈中，回顾其职业生涯及细胞治疗领域的变化。他提出开发者应在早期阶段优先重视产品表征与 CMC，并探讨了有望改善可扩展性的技术与生产策略。他还就行业如何将下一代变革性细胞疗法带给更多患者分享了看法。
In this video interview produced in partnership with IBTV, we sit down with John Tomtishen, Global Head of Cell Therapy Field Application Scientists and Strategic Alliances at Catalent, to discuss his career and the changes he has witnessed across the cell therapy field.
Tomtishen explains why developers should prioritize product characterization and CMC early in development, while exploring the technologies and manufacturing strategies that could improve scalability. He also shares his perspective on what the industry must do to bring the next generation of transformative cell therapies to more patients.
Watch the full interview below.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
来源：The Medicine Maker · themedicinemaker.com